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ABSTRACT
Objectives To explore criteria regulating treatment
with reimbursed biologic disease-modifying
antirheumatic drugs (bDMARDs) in patients with
rheumatoid arthritis (RA) across Europe and to relate
criteria to indicators of national socioeconomic welfare.
Methods A cross-sectional study among 46 European
countries. One expert from each country completed a
questionnaire on criteria regulating the start,
maintenance/stop and switch of reimbursed bDMARDs.
A composite score was developed to evaluate the level
of restrictions in prescription of a ﬁrst bDMARD
(0=highly restricted, 5=most liberal). The level of
restrictiveness was correlated with national
socioeconomic welfare indicators.
Results In 10 countries (22%), no bDMARD was
reimbursed. Among 36 countries with at least one biologic
reimbursed, 23(64%) had no requirement for disease
duration to initiate a biologic. Half of the countries required
a failure of two synthetic DMARDs to qualify for therapy.
31 countries speciﬁed a minimum level of disease activity
to be fulﬁlled and in 20 (56%) countries cut-off for disease
activity score with 28-joint assessment was higher than
3.2. Four countries (11%) had the maximum composite
score (most liberal) and 20 (56%) scored between 0 and 2
(more restrictive). Criteria for initiation of a bDMARD were
negatively associated with countries’ socioeconomic
welfare (−0.34 to −0.64), and a moderate positive
correlation was found between the composite score and
welfare indicators (0.59–0.72). Only some countries
had regulations for stopping (n=14(39%)) or switching
(n=19(53%)).
Conclusions Clinical criteria regulating prescription of
bDMARDs in RA differ signiﬁcantly across Europe.
Countries with lower socioeconomic welfare tend to have
stricter eligibility criteria, pointing to inequities in access to
treatment.
INTRODUCTION
In the treatment of patients with rheumatoid arth-
ritis (RA), the availability of biologic disease-
modifying antirheumatic drugs (bDMARDs)
improved the ability to control disease activity,
decreased the need for surgery and increased work
participation and quality of life.1 2 However,
bDMARDs are costly, and partly for this reason
reimbursement criteria and/or clinical recommenda-
tions/guidelines have been formulated across coun-
tries to regulate access to these treatments.3
We previously reported that access to conven-
tional treatment as well as biological treatment
across each dimension of access (availability, afford-
ability and acceptability) was more limited in coun-
tries with lower socioeconomic welfare.4 5 Access
to therapy was operationalised through system
characteristics (eg, price of bDMARDs, date of
reimbursement), while clinical criteria regulating
therapy were not covered.4 Discrepancies in these
criteria can contribute to inequalities in access and
consequently uptake of medications and health out-
comes. In 2009, Emery et al reviewed the clinical
guidelines for eligibility of patients with RA for
treatment with biologics in 10 European countries
and conﬁrmed large variations across countries,
particularly in terms of disease duration and disease
activity level required for initiation of anti-tumour
necrosis factor-α therapy.6 This review included
clinical guidelines published before 2007 and was
limited to a relatively small number of countries
from the European Union. Nowadays, more biolo-
gics are available for the treatment of RA, making it
important to also gain insight into criteria to stop
and switch between bDMARDs, and to explore the
possible existence of a maximum number of
bDMARDs that can be prescribed to one patient.
Moreover, no attempt has until now been made to
link variation in regulations to start a bDMARD
and the level of socioeconomic welfare of the
country and the uptake of bDMARDs or
RA-related health status in that country.
The objective of the present study was therefore
to review the criteria regulating treatment with
bDMARDs (including start and maintenance) in
patients with RA across the entire European
Region, relate them to indicators of national socio-
economic welfare and shed light on potential
impact of these criteria on uptake of treatments
and health outcomes.
METHODS
Data collection
All countries of the European Region were invited
to participate, with the exception of small
2010 Putrik P, et al. Ann Rheum Dis 2014;73:2010–2021. doi:10.1136/annrheumdis-2013-203819
Clinical and epidemiological research
 o
n
 28 June 2018 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-203819 on 12 August 2013. Downloaded from
 
(city)-states and Israel, which were excluded from the start, and
Kyrgyzstan, where it turned out to be impossible to establish
collaboration.4
Data on the eligibility for initiation and maintenance/stop or
switches between bDMARDs in patients with RA were collected,
as of May 2011, by a rheumatologist or an expert from each
country. Answers were carefully checked and collaborators were
contacted to conﬁrm the results.
First, experts were asked whether at least one bDMARD was
reimbursed. For those countries conﬁrming an ofﬁcial reim-
bursement, medical specialties authorised to prescribe biologics
to patients with RA were identiﬁed, as well as whether either
reimbursement criteria or clinical recommendations (or both)
were predominantly regulating prescription. Further, informa-
tion was collected on the following requirements before starting
a bDMARD (if applicable): (a) minimal disease duration; (b)
failure of synthetic DMARDs (sDMARDs), including type,
number and length of treatment; and (c) clinical criteria, such as
level of disease activity where applicable (eg, disease activity
score with 28-joint assessment—DAS287). Finally, questions
were asked on (a) time point to assess response; (b) require-
ments to alter the frequency and/or dose of a biologic; (c) cri-
teria to stop (or maintain, as reported) therapy with biologics;
(d) criteria to switch between agents; (e) existence and (if applic-
able) frequency of ofﬁcial controls on the adherence to the
reimbursement criteria; and (f) maximum number of biologics
that could be tried on one patient.
Data on indicators of socioeconomic welfare and health
status of RA patients
Data on the number of inhabitants and indicators of socio-
economic welfare (gross domestic product (GDP), total health
expenditure and median income) were collected for each
country. Values were retrieved from web-based sources (latest
available data for 2008–2011) and adjusted to purchasing power
parities (2010, expressed in international dollars, int.$).8–10
Data on RA health status and uptake of bDMARD (percent-
age of patients ever treated with a biologic) were available for
21 countries from the Quantitative Standard Monitoring of
Patients with RA (QUEST RA) study, a multinational cross-
sectional study of non-selected outpatients with RA on disease
outcome. This provided clinical information: DAS28; swollen
joint count; tender joint count; Health Assessment
Questionnaire11; Physician (MD) and Patient (PT) Global Visual
Analogue Scales and erythrocyte sedimentation rate.5 12
Computed variables and composite score for clinical
eligibility criteria
The individual criteria to assess eligibility for a ﬁrst biologic
(disease duration, disease activity level and number of
sDMARDs to be failed) were inspected and categorised into two
or three broad groups so that the most frequent patterns could
be identiﬁed (tables 1 and 2). In order to compute this compos-
ite score, requirement for a speciﬁc disease duration was cate-
gorised as ‘any requirement’ (0 point) or ‘no requirement’ (1
point); the number of sDMARDs to be failed as ‘more than
two’ (0 point), ‘two’ (1 point) and ‘less than two’(2 points) and
the level of disease activity (based on the level of DAS28 since
this appeared to be the criterion applied by most regulations) as
‘DAS28 cut-off >3.2 or its equivalent’ (0 point), ‘DAS28 cut-off
≤3.2 or its equivalent’ (1 point) and ‘no requirement’ (2
points). In addition, a composite score was computed for each
country, which was the simple sum of the scores on the individ-
ual criteria and varied between 0 and 5; the higher the score,
the easier the access. Criteria for stop/maintenance (at 6
months), switch and change of frequency/dose were also cate-
gorised after inspection into broad groups to reﬂect the patterns
(table 3).
Statistical analysis
Data were analysed for all countries using descriptive statistics.
Score on the individual criteria (original values) and composite
index were compared between the 27 EU and the 9 non-EU
countries by means of Mann–Whitney U test (skewed
distribution).
The association between the sources of prevailing regulation
(only reimbursement criteria, only clinical recommendations or
both) and the frequency of controls on prescriptions from the
regulating agencies was investigated through χ2 test.
Correlations (Spearman) were ﬁrst established between the
individual criteria for initiation of a ﬁrst bDMARD and, next,
between the crude individual criteria and the composite score
with (a) indicators of socioeconomic welfare; (b) uptake of
bDMARDs; and (c) indicators of RA health status. Analysis was
done for all countries and EU countries separately. Coefﬁcients
>0.5 but ≤0.80 were assumed to be moderate and >0.8
strong.13 SPSS V.19.0 was used.
RESULTS
In total, 46 countries (response rate 94%) provided data. An
overview of the clinical criteria for eligibility and maintenance
of biologic in each of the countries is presented in table 1. In 10
countries (22%), no bDMARD was reimbursed. Among the
remaining 36, Luxemburg had no regulation for the start of a
reimbursed bDMARD, in 11 (31%) reimbursement criteria were
the major source of eligibility criteria, while in 7 (19%) clinical
recommendations predominated and in 16 (44%) both reim-
bursement criteria and clinical recommendations were used
(usually because they were similar or clinical criteria comple-
mented reimbursement criteria) for decisions to start a biologic
(table 1). Albania had no written source of regulation but
reported the criteria used in practice. Countries differed with
respect to frequency of controls of the adherence to formal
recommendations. Thirteen countries (36%) reported controls
were ‘frequent’ or ‘always’, in 17 countries (47%) controls were
‘rare’ or ‘sometimes’ and respondents from six countries (17%)
reported no controls of adherence to existing criteria. No asso-
ciation between the type of prevailing regulation (ie, reimburse-
ment criteria, clinical recommendations or both) and reported
frequency of controls was detected (p=0.43).
In 24 countries (67%), only rheumatologists had permission
to prescribe bDMARDs to patients with RA, while in the rest
other specialties such as Dermatology (22%), Gastroenterology
(22%), Internal medicine (25%), General practice (11%) and
other (14%) were similarly entitled to prescribe (table 1).
Among 36 countries with at least one biologic reimbursed, 23
(64%) had no requirement on disease duration to initiate a
bDMARD, while for the remaining countries the prespeciﬁed
minimum duration ranged from 3 to 12 months. With respect to
the number of sDMARDs to be failed, the most common criter-
ion (n=18(50%)) was the failure of two DMARDs. A minimum
level of disease activity or severity was mandatory in 31 (86%)
countries but was not speciﬁed in Germany, Ireland, Luxemburg,
Malta and Switzerland. In 11 countries (31%), patients with a
DAS28 of 3.2 qualiﬁed to obtain access to bDMARDs, but in 20
countries (ie, over 50%) this requirement was stricter than a
DAS28 of 3.2 (or equivalent), meaning that the cut-off to start a
biologic was higher than 3.2 (tables 1 and 2).
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Table 1 Clinical criteria for eligibility and maintenance of treatment with bDMARDs in 36 European countries with at least one biologic reimbursed
Country
Major source
of eligibility
criteria
Who can prescribe
bDMARDs to
patients with RA
Requirement to start the first biologic Time point for
the first
assessment of
response
(weeks)
Criteria to
stop at
6 months*
Criteria to switch at
6 months*
Composite score
for
restrictiveness of
clinical criteria
(0–5)
Minimum
disease
duration Level of disease activity
Number of sDMARDs
to be failed, type of
DMARD and length
Albania (no written
source provided,
criteria reported are
those used in
practice according
to contact person)
REIM Rheumatology No requirement DAS28>4.5 2 sDMARDs: MTX
(20 mg/week) and SSZ
(2.5 g/day)
NA No criteria No criteria 2
Austria24–26 REIM=GUID Rheumatology No requirement Moderate to high disease
activity
1 sDMARD: MTX in
adequate dose and
adequate duration
12 No criteria Moderate disease activity 4
Belgium27 REIM Rheumatology No requirement DAS28>3.7 2 sDMARDs: MTX
(15 mg/week)+another
DMARD
24 DAS28>5.1
and
improvement in
DAS28 <1.2
OR
DAS28 <5.1
and
improvement in
DAS28 <0.6
No criteria 2
Bulgaria28 REIM Rheumatology 6 months DAS28>5.1 2 sDMARDs: MTX
(20 mg/week) and LEFL
(20 mg/day) for 6 months
12 No criteria No criteria 1
Croatia29–31 REIM=GUID Rheumatology 6 months DAS28>5.1 AND HAQ 1.0–2.5
AND TJC>6 AND SJC>6 AND
ESR>28 AND CRP>12 AND ACR
I–III
2 sDMARDs: MTX
(20 mg/week)+another
DMARD for 6 months
12 (DAS28>3.2
and
improvement in
DAS28 <1.2)
OR
improvement
lower than
ACR20
No criteria 1
Cyprus32 REIM=GUID Rheumatology
+Dermatology
+Gastroenterology
+Internal medicine
6 months DAS28>4 2 sDMARDs: MTX
+another DMARD for at
least 6 months
12–16 DAS28>3.2
and
improvement in
DAS28<1.2
DAS28>3.2 and
improvement <1.2
1
Czech Republic33 34 REIM=GUID Rheumatology 6 months DAS28>3.9 1 sDMARD:, MTX
(20 mg/week) OR LEFL
(20 mg/day) OR SSZ (2 g/
day) for 3–6 months
12–16 No criteria Moderate disease activity 2
Denmark35 GUID Rheumatology No requirement DAS28>3.2 OR radiographic
progression
2 sDMARDs: MTX
(25 mg/week) and SSF
(2 g/day)
12–16 No criteria No criteria 3
Estonia36 37 REIM+GUID Rheumatology 6 months DAS28>4.6 AND TJC>8 AND
SJC>6 AND morning
stiffness>1 h AND ESR 30 AND
CRP 25 mg/L AND active visceral
disease by expert opinion
4 sDMARDs: including
MTX (25 mg/week) and
Prednisone (7.5 mg/
week)
12–24 Improvement in
DAS28<1.2
DAS28>4.6 AND TJC>8
AND SJC>6 AND morning
stiffness>1 h AND ESR 30
AND CRP 25 mg/L AND
active visceral disease by
expert opinion
0
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Table 1 Continued
Country
Major source
of eligibility
criteria
Who can prescribe
bDMARDs to
patients with RA
Requirement to start the first biologic Time point for
the first
assessment of
response
(weeks)
Criteria to
stop at
6 months*
Criteria to switch at
6 months*
Composite score
for
restrictiveness of
clinical criteria
(0–5)
Minimum
disease
duration Level of disease activity
Number of sDMARDs
to be failed, type of
DMARD and length
Finland38 REIM Rheumatology
+Internal medicine
No requirement Active disease 3 sDMARDs NA No criteria No criteria 2
France39 GUID Rheumatology
+Internal medicine
No requirement DAS28>5.1 OR lower if
corticodependence or structural
damage progression
None to 1 sDMARD: for
the majority of biologics,
only MTX is mentioned
without any strict dose
or regimen
12 No criteria No criteria 3
Germany40 REIM+GUID Rheumatology
+Dermatology
+Gastroenterology
+Internal medicine
+GP+other specialties
No requirement
(min. 3 months
recommended)
No requirement No requirement (2
sDMARDs: including
MTX, LEF, SSZ, HCQ,
Gold and CyA
recommended)
12 No criteria No criteria 5
Greece40a REIM+GUID Rheumatology No requirement DAS28>5.1 or
DAS28>3.2 AND presence of
adverse prognostic factors *
(≥2/5)
*Adverse prognostic factors: RF/
anti-CCP, joint erosions in X-ray,
HAQ>1, large joint involvement
and extra-articular disease
1. In established RA: 2
sDMARD either MTX
(≥15 mg/week) or LEFL
(20 mg/day) or 1
sDMARD if adverse
prognostic factors* (≥2/
5)
2. In early RA anti-TNF
agents are allowed
(combined to MTX) as
the first therapy in case
of highly active disease
(DAS28>5.1) AND
presence of adverse
prognostic factors* (>2/
5)
12 DAS28>3.2 DAS28>3.2 2
Hungary42 43 REIM+GUID Rheumatology 3 months DAS28>5.1 2 sDMARDs: MTX and
another sDMARD in ‘full
dose or tolerable dose’
12 Improvement
DAS28 <1.2
Improvement in DAS28
<1.2
1
Iceland41 REIM+GUID Rheumatology
+Dermatology
+Gastroenterology
No requirement DAS28 3.2 (progressing
radiographic damage facilitates
initiation of biologics)
1 sDMARD: MTX (20 mg/
week)
24 No criteria DAS28>3.2 4
Ireland44 GUID Rheumatology
+Dermatology
+Gastroenterology
+Internal medicine
+other specialties
No requirement No requirement 1 sDMARD: MTX (25 mg/
week) for 3 months
12 No criteria No criteria 5
Italy45 GUID Rheumatology
+Dermatology
+Gastroenterology
3 months DAS28>3.2 1 sDMARD: MTX (15 mg/
week) for 3 months
NA No criteria No criteria 3
Latvia46 REIM Rheumatology No requirement DAS28>3.2 3 sDMARDs: MTX
(20 mg/week)+another 2
DMARDs for 3–6 months
12 No criteria DAS28>3.2 2
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Table 1 Continued
Country
Major source
of eligibility
criteria
Who can prescribe
bDMARDs to
patients with RA
Requirement to start the first biologic Time point for
the first
assessment of
response
(weeks)
Criteria to
stop at
6 months*
Criteria to switch at
6 months*
Composite score
for
restrictiveness of
clinical criteria
(0–5)
Minimum
disease
duration Level of disease activity
Number of sDMARDs
to be failed, type of
DMARD and length
Lithuania47–49 REIM=GUID Rheumatology No requirement DAS28>5.1 2 sDMARDs: choice MTX
(25 mg/week) for
3 months, AZATH
(100 mg/day) for
3 months, LEFL (20 mg/
day) for 3 months, HCQ
(400 mg/day) for
3 months and SSZ (2 g/
day) for 6 months
12 Improvement in
DAS28 <1.2
after 3 months
Improvement in DAS28
<1.2 after 3 months
2
Luxemburg No regulation
in access to
reimbursed
biologics
Rheumatology
+Dermatology
+Gastroenterology
+Internal medicine
+GP+other specialties
No requirement No requirement No requirement NA No criteria No criteria 5
Macedonia50 REIM Rheumatology No requirement DAS28>4.2 AND SJC>=6 2 sDMARDs for 6 months 6–12 No criteria No criteria 2
Malta51 REIM Rheumatology 6 months No requirement 2 sDMARDs: choice MTX
for 6 months (at least
2 months on 15 mg/
week), LEFL (20 mg/day)
for months and SSZ (2 g/
day)
12 DAS28>3.2
and
improvement in
DAS28 <1.2
No criteria 3
Montenegro52 REIM Rheumatology 6 months DAS≥5.1 AND HAQ between 1
and 2.5 AND ACR I–III AND
increased ESR and CRP AND
SJC≥6 AND Painful joints ≥6
2 sDMARDs: choice MTX
(20 mg/week), SSZ (2 g/
day) and LEFL(20 mg/
day) for 3 months each
NA No criteria Improvement in DAS28
<1.2
1
The Netherlands53 REIM+GUID Rheumatology No requirement DAS28>3.2 2 sDMARDs: MTX and
another sDMARD
NA Improvement in
DAS28 <1.2
Improvement in DAS28
<1.2
3
Norway54 REIM=GUID Rheumatology No requirement DAS28≥3.2 1 sDMARD 12–24 No criteria No criteria 4
Poland55 REIM Rheumatology 12 months DAS28>5.1 OR DAS>3.7 if
joints of lower limbs are
involved
2 sDMARDs: MTX
(25 mg/week) for at least
3 months+another
DMARD
9 Improvement in
DAS28<1.2 in
90 days
Improvement in DAS28
<1.2 in 90 days
1
Portugal56 REIM+GUID Rheumatology
+Internal medicine
No requirement DAS>3.2 OR
2.6<DAS <3.2 AND (worsening
of HAQ>0.22 (6/6M) OR
worsening of X-ray scores:
Larsen>6/SvdH>5 (12/12M))
1 sDMARD: MTX in
conventional dose for
3 months or another
DMARD for 6 months
12 Improvement in
DAS28<1.2
OR
Improvement in
DAS28<0.6 in
3 months
Improvement in
DAS28<1.2
OR
<0.6 in 3 months
4
Romania57 REIM+GUID Rheumatology No requirement DAS28>5.1, including minimum
five joints with active synovitis
AND at least two of the
following: morning
stiffness>60 min AND ESR 1
h>28 OR CRP>20 mg/mL
2 sDMARDs: choice MTX
(20 mg/week), SSZ (3 g/
day) and LEFL (20 mg/
day) for 12 weeks each
24 No criteria DAS28 is stable≥5.1 or
improvement in DAS28
<1.2 between two separate
evaluations
2
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Table 1 Continued
Country
Major source
of eligibility
criteria
Who can prescribe
bDMARDs to
patients with RA
Requirement to start the first biologic Time point for
the first
assessment of
response
(weeks)
Criteria to
stop at
6 months*
Criteria to switch at
6 months*
Composite score
for
restrictiveness of
clinical criteria
(0–5)
Minimum
disease
duration Level of disease activity
Number of sDMARDs
to be failed, type of
DMARD and length
Serbia58 59 REIM+GUID Rheumatology 6 months Immediate and high activity
(ACR I–III/DAS28>5.1 AND HAQ
1–2.5), high evolution
2 sDMARDs: MTX
(7.5 mg/week) for at
least 6 months AND
choice: PRED (7.5 mg/
day) at least 1 month or
SSZ (500 mg/day) at least
1 month
12–16 No criteria Improvement in DAS28
<1.2
1
Slovakia60 GUID Rheumatology 6 months Moderate to high disease
activity
1 sDMARD: MTX (15 mg/
week) for 3 months
12 No criteria Moderate disease activity 3
Slovenia61 REIM=GUID Rheumatology No requirement DAS28>4.2 AND SJC>=8 2 sDMARDs: MTX
(20 mg/week) and choice
LEFL (20 mg/day) or SSZ
(2 g/day)
24 Improvement in
DAS28<1.2
No criteria 2
Spain62 62a GUID Rheumatology No requirement DAS28≥3.2 OR SDAI≥11OR
[(DAS28 between 2.6 - 3.2 OR
SDAI 5-11) AND (persistent
inflammation in joints
considered important for the
patient that does not resolve
with local therapies or
significant radiographic
progression)]
1 sDMARD: MTX (25 mg/
week)
12 No criteria DAS28≥3.2 OR
SDAI≥11OR [(DAS28
between 2.6 - 3.2 OR SDAI
5-11) AND (persistent
inflammation in joints
considered important for
the patient that does not
resolve with local therapies
or significant radiographic
progression)]
4
Sweden63 64 GUID Rheumatology
+Dermatology
+Gastroenterology
+Internal medicine
+GP+other specialties
No requirement DAS28>3.2 and several negative
prognostic factors OR
DAS28>5.1
No requirement 12 No criteria DAS28>3.2 and several
negative prognostic factors
3
Switzerland65–67 REIM Rheumatology
+Dermatology
+Gastroenterology
+Internal medicine
+GP
No requirement No requirement 1 sDMARD NA No criteria No criteria 5
Turkey68 REIM Rheumatology+other
specialties
No requirement DAS28>5.1 3 sDMARDs, including
MTX
12 Improvement in
DAS28 <1.2
OR
improvement in
DAS28 <0.6 in
3 months
No criteria 1
UK69 70 REIM Rheumatology 6 months DAS28>5.1 2 sDMARDs, including
MTX
26 Improvement in
DAS28<1.2
Improvement in DAS28
<1.2
1
*When criteria at different time points were defined, these are also added in the table with the corresponding information on the respective time point.
ACR, American College of Rheumatology; Anti-CCP, cyclic citrullinated peptide; AZATH, azathioprine; CRP, C reactive protein; Cya, cyclosporine; DAS28, disease activity score with 28-joint assessment; DMARD, disease-modifying anti-rheumatic drugs; ESR,
erythrocyte sedimentation rate; GP, general practitioner; GUID, national guideline; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; LEFL, leflunomide; MTX, methotrexate; PRED, prednisolone; RA, rheumatoid arthritis; REIM,
reimbursement criteria; RF, rheumatoid factor; SDAI, Simple Disease Activity Index; sDMARD, synthetic disease-modifying antirheumatic drugs; SJC, swollen joint count; SSZ, sulfasalazine; TJC, total joint count; TNF, tumour necrosis factor.
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Table 3 Summary of clinical eligibility criteria for stop of the therapy, switch to another bDMARD or change frequency/dose of a biologic for European countries with at least one biologic
reimbursed (n=36)
Stop due to inefficacy based on 6 -month assessment Switch based on 6-month assessment Change of frequency/dose
Criteria* N (%) Countries Criteria* N (%) Countries Criteria N (%) Countries
Not specified 22 (61%) AL, AT, BG, CZ, DK, FI, FR, DE, IS,
IE, IT, LV, LU, MK, ME, NO, RO,
RS, SK, ES, SE and CH
Not specified 17 (47%) AL, BE, BG, HR, DK, FI, FR,
DE, IE, IT, LU, MK, MT, NO,
SL, CH and TR
Not
specified
18 (50%) AL, AT, BE, BG, HR, EE, FI,
FR, DE, LV, LU, ME, NL, PL,
PT, SE, UK and MK
Yes, in terms of
disease activity level 7
(19%)
DAS28≥3.2 5 (14%) CY, MT, HR, HU and BE Yes, in terms of disease
activity level 11 (31%)
DAS28≥3.2 6 (17%) CY, GR, IS, LV, ES and SE Yes,
frequency
15 (42%) CY, CZ, DK, GR, IS, IE, IT,
MT, NO, RO, RS, SL, ES, CH
and TR
DAS28>4.6 † 1 (3%) EE
DAS28>5.1 1 (3%) RO Yes, dose 18 (50%) CY, CZ, DK, GR, IS, IE, IT, LT,
MT, NO, RO, RS, SK, SL, ES,
CH, TR and HU
Moderate
disease activity
3 (8%) AT, CZ and SK
Yes, in terms of DAS28
improvement 14 (39%)
Δ <0.6 1 (3%) BE Yes, in terms of DAS28
improvement10 (28%)
Δ<0.6 in
3 months
1 (3%) PT
Δ <1.2 14 (39%) BE‡, HR, CY, EE, GR, HU, MT, NL,
PT, SL, TR, UK, LT§ and PL§
Δ<1.2 10(28%) CY, HU, LT§, ME, NL, PL§,
PT, RO, RS and UK
*Countries could have more than one criterion to stop/switch (disease activity level and/or disease activity improvement).
†Additional clinical criteria have to be satisfied besides the specified level of DAS28, for example, additional requirement for radiographic damage or specific levels of swollen joint count and/or total joint count.
‡If DAS28>5.1.
§After 3 months.
bDMARD, biologic disease-modifying antirheumatic drugs; DAS28, disease activity score with 28-joint assessment.
AL, Albania; AT, Austria; BE, Belgium; BG, Bulgaria; CH, Switzerland; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; EE, Estonia; ES, Spain; FI, Finland; FR, France; GR, Greece; HR, Croatia; HU, Hungary; IE, Ireland; IS, Iceland; IT, Italy; LT,
Lithuania; LU, Luxemburg; LV, Latvia; ME, Montenegro; MK, Macedonia; MT, Malta; NL, the Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, Serbia; SE, Sweden; SK, Slovakia; SL, Slovenia; TR, Turkey; UK, United Kingdom.
Table 2 Summary of clinical criteria for initiation of a first bDMARD for European countries with at least one biologic reimbursed (n=36)
Minimal clinical requirements for initiation of a bDMARD
Disease duration DAS28 level Number of sDMARDs to be failed
N (%) Countries Score* N (%) Countries Score* N (%) Countries Score*
No
requirement
23 (64%) AL, AT, BE, DK, FI, FR, DE,GR, IS, IE, LV,
LT, LU, MK, NL, NO, PT, RO, SL, ES, SE,
CH and TR
1 No requirement 5 (14%) DE, IE, LU, MT and CH 2 <2 14 (39%) AT, CZ, FR, DE, IS, IE, IT, LU, NO, PT,
SK, ES, SE and CH
2
<6 months 12 (33%) BG, HR, CY, CZ, EE, HU, IT, MT, ME, RS,
SK and UK
0 Up to and
including 3.2
11 (31%) AT, DK, FI, IS, IT, LV, NL, NO, PT, SK and
ES
1 2 18 (50%) AL, BE, BG, HR, CY, DK, GR, HU, LT,
MK, MT, ME, NL, PL, RO, RS, SL and
UK
1
≥6 months 1 (3%) PL 0 Above 3.2 20 (56%) AL, BE, BG, HR, CY, CZ, EE, FR, GR, HU,
LT, MK, ME, PL, RO, RS, SL, SE, TR and
UK
0 >2 4 (11%) EE, FI, LV and TR 0
*Score is the contribution to the composite score for restrictiveness of clinical criteria for initiation of a biologic disease-modifying antirheumatic drugs (bDMARD). DAS28, disease activity score with 28-joint assessment; DMARD, disease-modifying
antirheumatic drug; sDMARDs, synthetic disease-modifying antirheumatic drugs.
AL, Albania; AT, Austria; BE, Belgium; BG, Bulgaria; CH, Switzerland; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; DK, Denmark; EE, Estonia; ES, Spain; FI, Finland; FR, France; GR, Greece; HR, Croatia; HU, Hungary; IE, Ireland; IS, Iceland;
IT, Italy; LT, Lithuania; LU, Luxemburg; LV, Latvia; ME, Montenegro; MK, Macedonia; MT, Malta; NL, the Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, Serbia; SE, Sweden; SK, Slovakia; SL, Slovenia; TR, Turkey; UK, United Kingdom.
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The timing for the ﬁrst assessment of response was speciﬁed
in 29 countries and varied from 9 to 24 weeks, with 16 coun-
tries deﬁning this period as 12 weeks. Fourteen countries (39%)
reported to have speciﬁc criteria to stop bDMARD before or at
6 months due to inefﬁcacy (or for maintenance, from which
stop criteria were extrapolated) (table 3). Of those, 11 (31%)
required a minimum improvement in terms of disease activity
(improvement of 1.2) before or at 6 months for therapy to be
continued. Five of these countries (14%) required in addition a
prespeciﬁed minimum level of disease activity to be achieved
and this level corresponded to low disease activity (ie, DAS28 of
3.2) in four of them.
More than half of the countries (n=19, 53%) reported there
were speciﬁc criteria for switching. These criteria included a
minimum level of disease activity (n=11, 31%) and/or failure
to reach a minimum improvement in disease activity (n=10,
28%). Half of the countries (n=18, 50%) had some regulation
regarding the possibility to change the frequency and/or dose
of a biologic (table 3). So far, no country introduced a
maximum number of biologics that can be prescribed to one
patient.
As for the composite score for clinical eligibility criteria that
was based on the three criteria to initiate a bDMARD, 4 coun-
tries (11%) had the maximum (5) eligibility score (most liberal),
12 countries (33%) had score 3 or 4 and 20 (56%) scored
between 0 and 2. Countries from Eastern Europe and Former
Soviet Union were more likely to be classiﬁed in the more
restricted scores (table 1, ﬁgure 1).
Figure 1 Composite score for restrictiveness of clinical criteria for initiation of a ﬁrst reimbursed biologic (0–5) in the European Region (score is
composed of (1) minimum required disease duration, (2) number of sDMARDs that have to be failed and (3) the level of DAS28). DAS28, disease
activity score with 28-joint assessment; sDMARDs, synthetic disease-modifying antirheumatic drugs.
AL, Albania; AT, Austria; BE, Belgium; BG, Bulgaria; HR, Croatia; CY, Cyprus; CZ, Czech Republic; EE, Estonia; FI, Finland; FR, France; DE, Germany;
DK, Denmark; GR, Greece; HU, Hungary; IS, Iceland; IE, Ireland; IT, Italy; LV, Latvia; LT, Lithuania; LU, Luxemburg; MK, Macedonia; MT, Malta;
ME, Montenegro; NL, the Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, Serbia; SK, Slovakia; SL, Slovenia; ES, Spain;
SE, Sweden; CH, Switzerland; TR, Turkey; UK, United Kingdom.
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The results for the eligibility for a ﬁrst bDMARD did not
differ signiﬁcantly between the 27 EU and 9 non-EU members,
neither for the individual criteria nor for the composite score
(data not shown).
Correlation of clinical criteria and composite score for the
eligibility for ﬁrst biologic with GDP, uptake of bDMARDs
and health status
The three individual clinical criteria to start a bDMARD were
positively but weakly correlated with each other (Spearman
coefﬁcients 0.23–0.43), with the strongest association between
the required level of disease activity and the number of
sDMARDs to be failed (data not shown).
The level of DAS28 required before starting a bDMARD was
moderately negatively associated with socioeconomic indicators
(ﬁgure 2), weakly positively with the indicators of health status
of RA patients and weakly negatively with the uptake of
bDMARDs. The number of sDMARDs to be failed and require-
ment for minimum disease duration followed similar patterns
(table 4).
The composite score was moderately positively associated
with socioeconomic welfare and weakly to moderately nega-
tively with the indicators of health status. Importantly, the com-
posite score correlated moderately positively with the available
data on the uptake of biologics. When analyses were limited to
the 27 EU member states, correlations were weaker but the dir-
ection of the associations persisted (table 4).
DISCUSSION
This study highlights differences in clinical criteria that regulate
initiation and continuation of treatment with reimbursed
bDMARDs in patients with RA across the European Region. A
ﬁrst and foremost ﬁnding was that in 10 countries (all non-EU)
no bDMARDs were reimbursed. In countries with bDMARDs
reimbursed (n=36), criteria mainly regulated the start of the
ﬁrst biologic (all countries) in contrast with regulations for stop-
ping/maintaining (n=14, 39%) or switching between drugs
(n=19, 53%), which were not deﬁned in every country. Limited
regulations to stop bDMARDs are remarkable, because substan-
tial costs can potentially be saved by stopping costly drugs that
are (or have become) ineffective. On this line it is interesting to
see that several new studies explore the impact of stopping
bDMARDs in patients with sustained remission.14
Strikingly, in more than half of the countries (56%) the
cut-off for the DAS28 as a criterion to start the ﬁrst biologic
was stricter than 3.2 (DAS28≥3.2). Furthermore, 13 countries
(36%) required a minimum disease duration and 22 (61%) spe-
ciﬁed that more than one sDMARDs had to be failed before a
bDMARD can be initiated.
Overall, the composite eligibility score indicated highly
restricted access in one-third of the countries (scores 0 and 1). A
strong negative association between the eligibility and GDP was
found. Particularly non-EU countries had stricter eligibility cri-
teria. In many of these countries the eligibility criteria tended to
be stricter than The European League Against Rheumatism
(EULAR) recommendations and were not following the
treat-to-target recommendations.15 16
Figure 2 Composite score for restrictiveness of clinical criteria (0–5) and GDP per capita (int/$), n=36. Size of the bubble is proportional to the
population size of each country. Dashed trend line is added to show the linear trend if without data from Luxemburg, which can be considered an
outlier GDP, gross domestic product.
AL, Albania; AT, Austria; BE, Belgium; BG, Bulgaria; HR, Croatia; CY, Cyprus; CZ, Czech Republic; EE, Estonia; FI, Finland; FR, France; DE, Germany;
DK, Denmark; GR, Greece; HU, Hungary; IS, Iceland; IE, Ireland; IT, Italy; LV, Latvia; LT, Lithuania; LU, Luxemburg; MK, Macedonia; MT, Malta; ME,
Montenegro; NL, the Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, Serbia; SK, Slovakia; SL, Slovenia; ES, Spain; SE, Sweden;
CH, Switzerland; TR, Turkey; UK, United Kingdom.
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The present study expands on the existing knowledge. First,
46 countries were surveyed covering nearly all European
Region, thus providing more comprehensive picture regarding
the regulations of prescriptions of bDMARDs as compared with
previous studies.6 17 Second, geographic variations in criteria
regulating initiation of a ﬁrst biologic were seen in their relation
to countries’ socioeconomic welfare, which expanded on study
previously reported by Pease et al.17
Within the limitations of availability and generalisability of
data on medication uptake and RA health status across coun-
tries, our ﬁndings are alarming as stricter clinical eligibility cri-
teria seem to also be associated not only with lower uptake of
biologics, but also with higher disease activity, thus suggesting
that principles of equitable heathcare systems might be under-
mined within Europe. This ﬁnding was similar in EU and
non-EU countries.
The study has some limitations. First, data were reported by
one expert per country and we could not review the full texts of
regulations (often published in local language only). However,
contact persons were asked to clarify and check the results.
Second, data on the health status and uptake of bDMARDs
were only available from a single study conducted between
2005 and 2008 in a limited number of countries.5 Nevertheless,
to our knowledge it represents the best available international
data on health status in patients with RA. We recognise that a
large number of factors have to be considered in order to under-
stand the relation between eligibility criteria and uptake of
bDMARDs or health outcomes and many were not assessed in
our study. First, the development of the composite score used to
compare the restrictiveness of the criteria for initiation of a ﬁrst
bDMARD was not data-driven and should be interpreted with
caution. It may be a line of further research to develop a vali-
dated tool to monitor the restrictiveness of criteria across coun-
tries in relation to health outcomes, which would inform policy
makers in deﬁning the major cut-off points. Next, the results do
not take into account the regional variations that can exist
within the countries.18 19 However, we believe that presented
data do provide a valuable insight into the patterns in eligibility
for biologic treatment within Europe and formulate challenges
for further research. Last but not the least, it should be empha-
sised that formal prescription requirements do not necessarily
reﬂect the actual practice. Adherence to requirements is a ques-
tion for further research, including the relevant question
whether within countries speciﬁc barriers or facilitators can be
identiﬁed at the level of the organisation and ﬁnancing as well
as at the level of prescribers and patients.20 21
In contrast to the situation in RA, national regulations in
ankylosis spondylitis (AS) were consistent with the recommen-
dations from the Assessment of SpondyloArthritis international
Society (ASAS) and EULAR.22 One of the reasons may be
limited conservative treatment options in AS that result in less
discussion on the clinical indication to start a biologic. Also, AS
is less prevalent and its impact on budget is of less concern for
policy makers. Furthermore, the existence of a speciﬁc society
for AS (ASAS) that makes efforts towards spreading knowledge
can play a role. Strengthening of the role of EULAR in aligning
the national guidelines according to the EULAR recommenda-
tions and helping countries to understand barriers against adapt-
ing guidelines might be essential on the way to equity
worldwide and this area of research is growing.23
In conclusion, the socioeconomic welfare of a country is asso-
ciated with the strictness of eligibility criteria stated in national
regulations to prescribe reimbursed treatment with bDMARDs.
This becomes unfair when universal right to healthcare is
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increasingly inﬂuenced by pure ﬁnancial considerations, and
patients in countries with lower budgets have stricter clinical
requirements to initiate a treatment that would be clinically
recommended at earlier stage. However, the problem is
complex and has to be treated within the national priorities on
public health agenda.
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